Doctor tells patient he doesn't have long to live through video screen

Re:Doctor tells patient he doesn't have long to live through... by zaroth on Friday March 08, 2019 @04:31PM (#19342387)

Purposefully priced?

Gilead did pay $11 billion to acquire Pharmasset and at one point was facing a $2.5 billion patent infringement ruling (later overturned) for that same drug.

AbbVie’s a new entrant which can treat certain strains at at about a third the cost.

Damn that Late Stage Capitalism developing a miracle cure for Hep C which is painless and effective.

[ Parent | on HN ]

Re:Doctor tells patient he doesn't have long to live through... by Pharmakon on Friday March 08, 2019 @10:32PM (#19344271)

This is the same AbbVie who’s treatment costs $26,000 right? I think it’s fair to say that’s priced well out of reach for most people, whatever the cost relative to Gilead’s product, which the CEO apologized for. The same AbbVie that sued the NHS? https://outline.com/brsHyA Incidentally Gilead made $5.8 billion in a single quarter so I think we can safely assume they managed to defray the cost of acquiring Pharmasset, don’t you think?

Companies making tens of billions a year while poor people suffer and die does seem to be a fairly negative situation, however you care to label it.

[ Parent | on HN ]

Re:Doctor tells patient he doesn't have long to live through... by RugnirViking on Saturday March 09, 2019 @08:39AM (#19346036)

I simply refuse to believe that treatments that cost the same as a brand new luxury car are down to labour + materials cost of some pills.

There are absurdly massive inefficiencies if as you say they aren't making profits.

[ Parent | on HN ]